Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489405 | 0.81 | DRD4 (0.54) | DRD4MEN1KMT2ATDP1CA1 | |
| SCHEMBL7809908 | 0.81 | DRD4 (0.54) | DRD4MEN1KMT2ATDP1CA1 | |
| SCHEMBL21408106 | 0.77 | CA12 (0.54) | DRD4MEN1KMT2ATDP1CA1 | |
| SCHEMBL893830 | 0.72 | TDP1 (0.67) | DRD4MEN1KMT2ATDP1MAOA | |
| SCHEMBL2635217 | 0.72 | CA2 (0.61) | KMT2ACA1CA2CA12CA4 | |
| SCHEMBL11179375 | 0.72 | TDP1 (0.67) | DRD4MEN1KMT2ATDP1MAOA | |
| Sulfuric Acid SCHEMBL28866056 | 0.72 | MEN1 (0.74) | MEN1KMT2ATDP1CA1CA2 | |
| SCHEMBL5764 | 0.71 | MEN1 (1.00) | DRD4MEN1KMT2ATDP1MAOA | |
| SCHEMBL18823259 | 0.71 | MEN1 (0.64) | DRD4MEN1KMT2ATDP1MAOA | |
| SCHEMBL1715809 | 0.71 | MEN1 (0.64) | DRD4MEN1KMT2ATDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-03-04 | — | — | US | disclosed |
| US-7625890-B2 | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors | SMITHKLINE BEECHAM CORP. (US) | 2009-12-01 | — | — | US | disclosed |
| WO-2008121685-A1 | METHODS OF USE FOR INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| EP-1948188-A2 | INHIBITORS OF AKT ACTIVITY | SmithKline Beecham Corporation (US) | 2008-07-30 | — | — | EP | disclosed |
| US-20080076763-A1 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC | 2008-03-27 | — | — | US | disclosed |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2007-05-31 | — | — | US | disclosed |
| WO-2007058850-A2 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2007-05-24 | — | — | WO | disclosed |
| US-7166598-B2 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases such as asthma, emesis, an anxiety disorder, pollakiuria, urinary incontinence and irritable bowel syndrome | ASTELLAS PHARMA INC. (JP) | 2007-01-23 | — | — | US | disclosed |
| EP-1140924-B1 | PIPERAZINE DERIVATIVES | ASTELLAS PHARMA INC (JP) | 2006-03-22 | — | — | EP | disclosed |
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014948-A1 | e.g 1-[3,5-bis(trifluoromethyl)benzoyl]-2-[3-[(2-methoxyethoxy)-methoxy]-4-methylbenzyl]-4-[2-[(3R)-3-methoxymethyl-morpholino]ethyl]piperazine; treating or preventing Tachykinin-mediated diseases in humans or animals | PKD2, TAC3, PKD1 | DRD4 1628/4885MEN1 519/4885KMT2A 709/4885 |
| US-20080076763-A1 | Inhibitors of Akt activity | PI4KB, PIK3CA, AKT2 | DRD4 4782/4885MEN1 3151/4885KMT2A 1852/4885 |
| US-20100056523-A1 | INHIBITORS OF AKT ACTIVITY | PI4KB, PIK3CA, AKT2 | DRD4 4782/4885MEN1 3151/4885KMT2A 1852/4885 |
| US-20070123532-A1 | PIPERAZINE DERIVATIVES | PKD2, SSTR5, IL5 | DRD4 752/4885MEN1 954/4885KMT2A 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.